SCHEMBL6033063

SCHEMBL6033063

Cc1nc(N)cc(-c2ccc3cccnc3c2C)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.47
PIK3CA P42336 6/20 0.47
MTOR P42345 4/20 0.47
PIK3CD O00329 2/20 0.47
PIK3CB P42338 2/20 0.47
PIK3CG P48736 2/20 0.47
CCR1 P32246 4/20 0.46
CCR8 P51685 4/20 0.46
CCR5 P51681 3/20 0.46
KDM4E B2RXH2 3/20 0.46
MAPT P10636 3/20 0.46
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
GMNN O75496 1/20 0.46
TP53 P04637 1/20 0.46
HSP90AA1 P07900 1/20 0.46
MMP2 P08253 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6034158 0.83 LMNA (0.47) LMNAMTORCCR1CCR8CCR5
SCHEMBL6034049 0.83 PIK3CA (0.44) LMNAPIK3CAMTORPIK3CDPIK3CB
SCHEMBL24412189 0.75 KDM4E (0.55) LMNAMTORCCR1CCR8CCR5
SCHEMBL114590 0.75 PIK3CA (0.53) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL6033091 0.72 ALDH1A1 (0.50) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL3070366 0.71 LMNA (0.63) LMNAMTORCCR1CCR8CCR5
SCHEMBL13982039 0.70 KDM4E (0.50) LMNAPIK3CAMTORPIK3CDPIK3CB
Phenanthroline SCHEMBL27821887 0.70 CCR1 (0.94) LMNAMTORCCR1CCR8CCR5
SCHEMBL6033683 0.70 LMNA (0.49) LMNAMTORCCR1CCR8CCR5
SCHEMBL27325118 0.69 LMNA (0.55) LMNAMTORCCR1CCR8CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685124-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2006-08-02 EP disclosed
US-20050197342-A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain HOLLINGWORTH GREGORY J (GB) 2005-09-08 US disclosed
WO-2005047279-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197342-A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain OPRL1, OPRK1, CNR1 LMNA 3939/4885PIK3CA 2679/4885MTOR 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.